Enveda's Radical Vision for the Future of Medicine | Viswa Colluru & Pablo Lubroth

Enveda Founder and CEO Viswa Colluru believes we have been looking for new medicines in the wrong places for decades.In the Season 1 finale of Forecast 2050, I sat down with Viswa and Pablo Lubroth, VP of Special Projects at Enveda, to discuss why 9 in 10 drugs fail in clinical trials despite Big Pharma spending $276 billion in annual R&D, how AI is finally unlocking 99% of nature's chemistry that we've haven't been able to read, why the incentive structure of biotech capital markets is actively bad for patients, why insisting on understanding how a drug works actually slows down drug discovery, why aging may not be inevitable, and why mental health is going to be the defining medical crisis of the next 25 years.Extended Show Notes: https://finnmurphyirl.substack.com/p/3dc95f79-4a7e-4c80-9630-970c1e6e2117Transcript (with helpful links!): https://finnmurphyirl.substack.com/p/beb7222d-efd1-472b-85be-09d7a7faf1a5Chapters:00:00 Intro01:09 The Quintessential Problem With Drug Discovery04:57 Pablo’s Journey to Enveda06:29 Insisting on Understanding Biological Mechanisms Slows Down Drug Discovery09:39 Science Has Been Divorced From Human Experience12:22 Scientific Reductionism Has Not Led to Better Drugs19:31 Lessons Learned From Big Pharma Missing Out On GLP-1s22:11 Capital Markets Disinventivize Risk-Taking and Harm Patients28:12 How to Prioritize Which Illnesses to Cure33:38 Prediction and Prevention is a Better Strategy Than Treatment38:27 Drugs to Make Us Limitless Like Bradley Cooper42:53 Aging is Not Inevitable43:34 Everyone Has a Chinese Peptide Guy50:13 The Loon Shots for 205052:39 Mental Health Will be The Biggest Challenge for 205054:46 The AI Revolution in MedicineViswa Colluru is the Founder & CEO of Enveda, a clinical-stage biotech company using AI to discover new drugs from nature. He built Enveda from $55K of personal savings into a unicorn with over $500M raised and multiple assets in clinical trials. Before founding Enveda, Viswa was the first Innovation Scientist and Product Manager at Recursion Pharmaceuticals. He holds a PhD in immuno-oncology from UW-Madison.Pablo Lubroth is a VP of Special Projects at Enveda and the Co-Founder & Editor of Decoding Bio. He previously built and led the biotech practice at Hummingbird Ventures and co-hosts the annual AI x Bio Summit at the NYSE. Pablo holds degrees in Neuropharmacology and Biochemical Engineering from UCL and an MPhil in Bioscience Enterprise from the University of Cambridge.Viswa on X: https://x.com/viswacolluruPablo on X: https://x.com/pablolubrothEnveda: https://enveda.comDecoding Bio: https://www.decodingbio.comForecast 2050 is a series about the next 25 years—and the builders, thinkers, and leaders shaping what comes next. Finn on X: https://x.com/FinnMurphy12Finn on LinkedIn: https://www.linkedin.com/in/finn-murphy-16160465/Nebular is a venture capital firm based in New York City. Head to nebular.vc for more info.